Navigation Links
Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire

CHARLESTON, S.C., Feb. 12 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid-induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced preliminary findings from its development and testing of an Opioid Symptoms Questionnaire, or OSQ, which will be used in Charleston's clinical trials.

"This pilot methodology study was designed to test the feasibility and reliability of the OSQ," reported Dr. Bernard Schachtel, Chief Scientific Officer at Charleston Labs. "All patients used the OSQ before and at intervals after ingesting different opioid drugs to indicate the presence and severity of symptoms caused by these medications.

"Using the OSQ prospectively, showing natural progression of opioid side effects," Dr. Schachtel continued, "patients detected different symptoms, not just nausea or vomiting, in good accordance with conventional methods, occasionally with better sensitivity. We will be presenting the final results from this version of the OSQ and other measurement instruments to our Scientific Advisory Board and the clinical investigators for their review and input before completing the protocol for our full-sized clinical trial."

This methodology study was conducted in preparation for Charleston's studies on patients who may experience OINV, the target indication for Charleston's first opioid drug, CL-108. Arrangements are being made with clinical investigators at major universities and research sites in the US to participate in a multi-centered double-blind, randomized, placebo-controlled, multiple-dose safety and efficacy study on over 1,000 patients with post-operative pain. The purpose of this Phase III study is to evaluate CL-108 for relief of acute moderately severe or severe pain and the reduction or elimination of OINV.

All clinical studies for Charleston Laboratories are being overseen by SRC, Inc., a contract research organization based in Jupiter, Florida, which specializes in clinical trials on patients' symptoms (such as nausea).

About Charleston Laboratories, Inc

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

SOURCE Charleston Laboratories, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Doug Flutie, Jr. Foundation Grants NAA $10,000 for Burbacher/Charleston Study
2. The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients
3. Charleston, S.C., Market Integration Likely to Drive Physician Groups to Seek Health System Affiliation
4. Charleston Laboratories, Inc. Phase I Clinical Trial
5. Hospital Clínic conducts the first kidney extraction through the vagina in Europe
6. LCA-Vision Conducts 2008 Annual Stockholder Meeting
7. iCRco Conducts First Annual Asia Pacific Distributor Training Program
8. AARP Responds to Senator Grassley, Conducts Comprehensive Review of Marketing of Fixed Benefit Indemnity Products
9. Pennsylvania State Health Department Conducts Pertussis Immunization Clinic in Mercer County
10. NASA Conducts Pilot Cognition Studies
11. New data on hormone therapy must lead to re-evaluation of official guidelines
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse ... of the staff members at their recovery center. The videos highlight some of the ... of the things that make their recovery program so unique. , “Making the decision ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron ... designed to yield insights into how to detect and treat pancreatic cancer (PC). ... from small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... has been designated an Aetna Institute of Quality® Bariatric Surgery Facility for treating ... quality and cost of health care services available to its members to help ...
(Date:11/24/2015)... ... ... Rodney E. Willey , has answered a new calling – to relieve snoring and sleep ... snoring and sleep apnea through oral appliance therapy. He is one of ... US, one of four in the Illinois area. , Dr. Willey’s location is ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty Health ... have announced their endorsement of the Medical Fitness Network (MFN), a national ... to have the MFN as one of our endorsed organizations,” said ASH Fitness ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 24, 2015 Sectra ... has entered into a multi-year agreement to deploy ... This investment will provide the Breast Center a future-proof ... Sectra (STO: SECT B) announces that Breast Center ... to deploy Breast Imaging PACS in its two freestanding ...
(Date:11/24/2015)... Mass. , Nov. 24, 2015   HeartWare ... innovator of less-invasive, miniaturized circulatory support technologies that are ... that President and Chief Executive Officer Doug Godshall ... 27 th Annual Healthcare Conference on December 1, ... held December 1-2 in New York ...
(Date:11/24/2015)... and BERN, Switzerland , ... the ARTORG Center for Biomedical Engineering Research of the ... the Division of Endocrinology, Diabetes and Clinical Nutrition of ... the start of an exclusive collaboration to develop a ... algorithm for the personalised delivery of insulin for diabetic ...
Breaking Medicine Technology: